How to Know When to Increase Your Mounjaro Dose

The biggest myth: dose increases are automatic after four weeks

A question our prescribers hear most weeks goes something like this: "My four weeks are up, should I go to the next pen?" It is an understandable assumption. The standard titration schedule does use roughly four-week intervals, and that structure exists for a reason: it gives your gut receptors time to adjust and lets most of the early nausea, reflux or loose stools settle before you add more stimulation. But the four weeks is a minimum, not an instruction to increase.

There are two conditions that both need to be met before a dose step makes sense. First, tolerability: if you are still managing meaningful nausea or digestive disruption at the current strength, moving up is likely to amplify those symptoms rather than push past them. Second, response: if appetite control is still working well and weight is moving, there is often no clinical reason to increase at all. Staying longer at a dose that is both tolerated and effective is a completely legitimate path. The full tirzepatide guide on our site covers the licensed dose range in more detail.

The myth worth correcting, then, is that higher always means better. For some people, 5 mg or 7.5 mg turns out to be their long-term maintenance strength. For others, reaching 10 mg or 15 mg is the point at which everything clicks. There is no universally correct rung, and no shortcut to finding yours.

What 'not working' actually looks like at your current dose

Understanding how to know when to increase your Mounjaro dose requires being precise about what "not working" means. The clearest signal is a genuine plateau: weight has been stable for three or four weeks, you are following the dietary guidance you agreed with your prescriber, and appetite suppression feels noticeably weaker than it did in the first two weeks at this strength. That combination is the classic sign that the current dose is no longer providing full coverage across the week.

A subtler signal is the "end of week" effect, hunger returning more sharply in the final two or three days before your next injection. This happens because the medicine's concentration in your bloodstream dips toward the end of the dosing interval, and at lower doses that dip can be more pronounced. If this pattern is consistent and affecting your eating behaviour, our detailed guide to when to increase your Mounjaro dose explains how to think through that decision before raising it with your prescriber. You can read more about the reasoning behind dose progression on our page covering why dose increases are considered.

What does not count as a reliable signal: a single static week on the scales, water-retention fluctuations, or the urge to speed things up because a friend is on a higher dose. Weight loss is not linear even on effective treatment, and comparing your dose to someone else's situation rarely tells you anything useful about your own.

Side effects as a reason to wait, or to discuss a different approach

If side effects are still present and disruptive at your current dose, increasing is generally not the right move yet. The NHS tirzepatide medicine page lists the most common effects (nausea, vomiting, diarrhoea, constipation, reflux and fatigue) and notes they are typically most noticeable after starting or after a step up. Giving the body a full four to six weeks, sometimes longer, before moving up is a reasonable and common approach.

There is also the question of what kind of side effects you are experiencing. Mild, manageable nausea that is already fading is very different from persistent vomiting or significant abdominal pain. The latter warrants a conversation with your prescriber or, if severe, medical attention, not a dose increase. Our guide to supporting weight loss on Mounjaro covers practical strategies, including dietary adjustments, that can help at any dose level without needing to go higher.

One note on serious symptoms: the MHRA issued specific guidance in early 2026 reminding patients and clinicians that acute pancreatitis is a known, if infrequent, side effect of GLP-1 medicines. Severe stomach pain that radiates to the back, with or without vomiting, should prompt urgent medical review, not a change of dose. You can report side effects through the MHRA Yellow Card scheme if you experience anything unexpected.

How the conversation with your prescriber works, and what to bring to it

At nume, every repeat order goes through a fresh clinical review. That review is when the dose question gets properly addressed, your prescriber looks at your progress, your reported side effects and your current strength before confirming whether continuing at the same dose or stepping up makes sense. This is not a formality; it is where the actual clinical judgement happens. You can read about how we approach that process on our about page.

You can make that review more useful by noting a few things before it: how appetite suppression has felt across the full week (not just the day after your injection), whether you have had consistent digestive symptoms, and how weight has moved over the past three to four weeks. Bringing that picture to your prescriber is far more useful than asking "can I go up?" in the abstract. For more on what the progression can look like over time, the weight-loss-focused dose timing page adds useful context.

For those managing the cost of ongoing treatment, understanding the process of obtaining Mounjaro through a regulated UK pharmacy is worth reading before your next review. And if you have broader questions about the titration schedule, our frequently asked questions section covers a range of common concerns. When you are ready to talk through your own situation with a prescriber, check your eligibility and start your free consultation with the nume clinical team.